BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $24.80.

Several equities research analysts have weighed in on the company. UBS Group cut BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Oppenheimer initiated coverage on BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They set an “outperform” rating and a $22.00 price target for the company. Wall Street Zen upgraded BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. JPMorgan Chase & Co. started coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $27.00 price objective on the stock. Finally, Canaccord Genuity Group started coverage on BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $23.00 price objective on the stock.

BridgeBio Oncology Therapeutics Stock Performance

Shares of BridgeBio Oncology Therapeutics stock opened at $8.09 on Friday. The company has a market cap of $648.09 million, a P/E ratio of -3.95 and a beta of 0.39. The stock’s 50 day moving average price is $8.17. BridgeBio Oncology Therapeutics has a 1-year low of $7.00 and a 1-year high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. As a group, equities analysts predict that BridgeBio Oncology Therapeutics will post -2.3 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Hedge funds have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $63,000. Persistent Asset Partners Ltd bought a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at approximately $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at approximately $144,000. Quadrature Capital Ltd acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter valued at approximately $162,000. Finally, BIT Capital GmbH acquired a new stake in BridgeBio Oncology Therapeutics in the fourth quarter valued at approximately $313,000. 54.89% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.